Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Bianka Sobolewska, Johanna Hofmann, Martin S. Spitzer, Karl U. Bartz-Schmidt, Peter Szurman & Efdal Yoeruek. (2013) Antiproliferative and Cytotoxic Properties of Moxifloxacin on Rat Retinal Ganglion Cells. Current Eye Research 38:6, pages 662-669.
Read now
Read now
Leyla Asena, Yonca A. Akova, Mustafa T. Goktaş, Atilla Bozkurt, Ümit Yaşar, Gülten Karabay & Ebru Demiralay. (2013) Ocular Pharmacokinetics, Safety and Efficacy of Intracameral Moxifloxacin 0.5% Solution in a Rabbit Model. Current Eye Research 38:4, pages 472-479.
Read now
Read now
Christina Ohnsman, David Ritterband, Terrence O’Brien, Dalia Girgis & Al Kabat. (2007) Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis. Current Medical Research and Opinion 23:9, pages 2241-2249.
Read now
Read now
Juan-Pablo Caeiro & Paul B Iannini. (2003) Moxifloxacin (Avelox®): a novel fluoroquinolone with a broad spectrum of activity. Expert Review of Anti-infective Therapy 1:3, pages 363-370.
Read now
Read now
Francesco Blasi, Paolo Tarsia, Roberto Cosentini, Mario Cazzola & Luigi Allegra. (2003) Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections. Expert Opinion on Investigational Drugs 12:7, pages 1165-1177.
Read now
Read now
Articles from other publishers (9)
Ijaz Ahmad, Lingli Huang, Haihong Hao, Pascal Sanders & Zonghui Yuan. (2016) Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction. BioMed Research International 2016, pages 1-12.
Crossref
Crossref
Paul Karpecki, Michael R. Paterno & Timothy L. Comstock. (2010) Limitations of Current Antibiotics for the Treatment of Bacterial Conjunctivitis. Optometry and Vision Science 87:11, pages 908-919.
Crossref
Crossref
M. Kernt, C. Hirneiss, A.S. Neubauer, R.G. Liegl, K.H. Eibl, A. Wolf, H. de Kaspar, M.W. Ulbig & A. Kampik. (2009) Moxifloxacin intrakameral: Eine sichere Option zur Endophthalmitisprophylaxe?Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis?. Der Ophthalmologe 107:8, pages 720-727.
Crossref
Crossref
Marcus Kernt, Aljoscha S Neubauer, Raffael G Liegl, Carl A Lackerbauer, Kirsten H Eibl, Claudia S Alge, Michael W Ulbig & Anselm Kampik A. (2009) Intracameral Moxifloxacin: In Vitro Safety on Human Ocular Cells. Cornea 28:5, pages 553-561.
Crossref
Crossref
Cesar Ramon G. Espiritu, Victor L. Caparas & Joanne G. Bolinao. (2007) Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. Journal of Cataract & Refractive Surgery 33:1, pages 63-68.
Crossref
Crossref
Mitchell H. Friedlaender, Daphne Breshears, Bahram Amoozgar, Heather Sheardown & Michelle Senchyna. (2006) The dilution of benzalkonium chloride (BAK) in the tear Film. Advances in Therapy 23:6, pages 835-841.
Crossref
Crossref
Terrence P. OʼBrien. (2006) Evidence-based Review of Moxifloxacin. International Ophthalmology Clinics 46:4, pages 61-72.
Crossref
Crossref
A. Liebetrau, A. C. Rodloff, J. Behra-Miellet & L. Dubreuil. (2003) In Vitro Activities of a New Des-Fluoro(6) Quinolone, Garenoxacin, against Clinical Anaerobic Bacteria. Antimicrobial Agents and Chemotherapy 47:11, pages 3667-3671.
Crossref
Crossref
Kelley A. Gordon, Paul R. Rhomberg & Ronald N. Jones. (2003) Commercial Broth Microdilution Panel Validation and Reproducibility Trials for Garenoxacin (BMS-284756), a Novel Desfluoroquinolone. Journal of Clinical Microbiology 41:8, pages 3967-3969.
Crossref
Crossref